Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha ...

Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments. The company will acquire ...

The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...

The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...

The company states: “Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha inhibitor program STX-478. STX-478 is a once-daily ...

The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors. The therapy is designed to target ...

The company will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors. The therapy is a ...

Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for ...